Novozymes Biopharma announces new study data using Recombumin in protein drug formulation
Novozymes Biopharma, part of Novozymes A/S, announced new data which demonstrates extended shelf life of protein drug products using Recombumin, recombinant human albumin. The data, presented for the first time at a recent protein-focused industry event, reveals the potential for Recombumin to reduce product loss by preventing the physical and chemical degradation of protein drugs.
A data sheet entitled "Recombumin®: A pharmaceutical excipient in the stabilization of therapeutic protein products" details the findings. The study investigated the ability of Recombumin, a recombinant human albumin expressed in Saccharomyces cerevisiae, to prevent the deterioration of protein drug products in a variety of test formulations. The study particularly addressed Recombumin's minimization of surface adsorption, oxidation and aggregation in comparison to excipients commonly used for the purpose of formulating protein drugs.
The new data demonstrates that Recombumin has the capacity to improve the shelf life of protein drug products. The study's findings indicate that Recombumin performed as well as and often better than the comparators making it an effective multi-purpose excipient with the capability to reduce the total number of excipients required and therefore simplifying the formulation strategy.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
